The tweet was deleted by the author.
But we saved everything 🙂.
Tyra Biosciences has begun its Phase 2 SURF302 study, investigating an oral FGFR3-selective inhibitor as a potential treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).
The company aims to expand treatment options for this patient group, which often faces recurring disease and requires ongoing monitoring and procedures. The announcement reflects Tyra Biosciences's focus on advancing innovative therapies for bladder cancer.
View post on X Loading...
Tyra Biosciences previously published a study in the Journal of Medicinal Chemistry on FGFR3-selective inhibitors for urologic cancers, including research on their approach to drug development. Details of this research were covered in a recent company update. The study highlights the company's ongoing work in targeted cancer therapies.